{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:59:05Z","timestamp":1770818345813,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.amjmed.2023.09.021","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:26:29Z","timestamp":1697113589000},"page":"137-146.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines"],"prefix":"10.1016","volume":"137","author":[{"given":"Caterina","family":"Mas-Llado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-8463","authenticated-orcid":false,"given":"Xavier","family":"Rossello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribel","family":"Gonz\u00e1lez-Del-Hoyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans Van","family":"de Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Tang","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Danchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen W-L","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2023.09.021_bib0001","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jacc.2016.03.600","article-title":"Achievements and limitations of evidence-based medicine","volume":"68","author":"Desmond","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0002","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2019.2018","article-title":"The evidence supporting cardiovascular guidelines: is there evidence of progress in the last decade?","volume":"321","author":"Bonow","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0003","doi-asserted-by":"crossref","unstructured":"Mas-Llado C, Gonz\u00e1lez-Del-Hoyo M, Siquier-Padilla J, et al: Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines [e-pub ahead of print]. Eur Heart J Qual Care Clin Outcomes.https:\/\/doi.org\/10.1093\/EHJQCCO\/QCAD007, accessed July 1, 2023.","DOI":"10.1093\/ehjqcco\/qcad007"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0004","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2015.10.014","article-title":"Making sense of statistics in clinical trial reports: part 1 of a 4-part series on statistics for clinical trials","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0005","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2021.06.024","article-title":"Primary and secondary outcome reporting in randomized trials: JACC State-of-the-Art Review","volume":"78","author":"Pocock","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0006","doi-asserted-by":"crossref","unstructured":"Gonzalez-Del-Hoyo M, Mas-Llado C, Siquier-Padilla J, et al: A systematic assessment of the characteristics of randomised controlled trials cited by acute coronary syndrome clinical practice guidelines [e-pub ahead of print]. Eur Heart J Qual Care Clin Outcomes. https:\/\/doi.org\/10.1093\/EHJQCCO\/QCAD034, accessed August 1, 2023.","DOI":"10.1093\/ehjqcco\/qcad034"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0007","doi-asserted-by":"crossref","unstructured":"Gonzalez-Del-Hoyo M, Mas-Llado C, Blaya-Pe\u00f1a L, et al: Type of evidence supporting ACC\/AHA and ESC clinical practice guidelines for acute coronary syndrome [e-pub ahead of print]. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/S00392-023-02262-9, accessed July 1, 2023.","DOI":"10.1007\/s00392-023-02262-9"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0008","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.286.6.708","article-title":"Representation of elderly persons and women in published randomized trials of acute coronary \u00edndromes","volume":"286","author":"Lee","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0009","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ejhf.1130","article-title":"Globalization of heart \u00edndrom clinical trials: a systematic review of 305 trials conducted over 16 years","volume":"20","author":"Vaduganathan","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0010","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2020.0359","article-title":"Enrollment of older patients, women, and racial\/ethnic minority groups in contemporary acute coronary syndrome clinical trials: a systematic review","volume":"5","author":"Tahhan","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009885","article-title":"Guideline-recommended therapies and clinical outcomes according to the risk for recurrent cardiovascular events after an acute coronary syndrome","volume":"7","author":"Hammer","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022198","article-title":"Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during 2005 to 2018 in the United States","volume":"11","author":"Steen","year":"2022","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0013","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0014","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ahj.2012.10.018","article-title":"EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study: rationale, design, and baseline characteristics","volume":"165","author":"Bueno","year":"2013","journal-title":"Am Heart J."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/clc.22431","article-title":"Rationale, design, and baseline characteristics of the EPICOR Asia study (Long-tErm follow-uP of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia)","volume":"38","author":"Huo","year":"2015","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0016","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0017","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0018","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0019","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0020","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","author":"Friedman","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0021","first-page":"57","article-title":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group","year":"1986","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0022","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0023","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0024","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","volume":"345","year":"1995","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0026","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0027","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1161\/01.CIR.95.12.2643","article-title":"Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial","volume":"95","author":"Pfeffer","year":"1997","journal-title":"Circulation."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0028","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0029","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0031","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijcard.2017.07.039","article-title":"Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality","volume":"245","author":"Rossell\u00f3","year":"2017","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0032","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00392-018-1254-y","article-title":"Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome","volume":"107","author":"Bueno","year":"2018","journal-title":"Clin Res Cardiol."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0033","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2459\/JCM.0000000000000889","article-title":"The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016","volume":"21","author":"Chen","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0034","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10557-019-06873-1","article-title":"Real world\u201d eligibility for sacubitril\/valsartan in unselected heart failure patients: data from the Swedish Heart Failure Registry","volume":"33","author":"Simpson","year":"2019","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/ehjqcco\/qcab070","article-title":"Generalizability of randomized controlled trials in heart failure with reduced ejection fraction","volume":"8","author":"Lim","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0036","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ehjcvp\/pvad012","article-title":"Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry","volume":"9","author":"Becher","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0037","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/ehjcvp\/pvab060","article-title":"Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)","volume":"8","author":"Rossello","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0038","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/clc.23261","article-title":"Eplerenone in patients with myocardial infarction and \u201cmid-range\u201d ejection fraction: an analysis from the EPHESUS trial","volume":"42","author":"Ferreira","year":"2019","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0039","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ejhf.1740","article-title":"Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials","volume":"22","author":"Rossello","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0040","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0195-668X(03)00315-4","article-title":"From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)","volume":"24","author":"Fox","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2023.09.021_bib0041","first-page":"911","article-title":"Assessment of quality indicators for acute myocardial infarction management in 28 countries and use of composite quality indicators for benchmarking","volume":"9","author":"Rossello","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0042","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ehjqcco\/qcac041","article-title":"EURObservational Research Programme: a bibliometric assessment of its scientific output","volume":"8","author":"Rossello","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"10.1016\/j.amjmed.2023.09.021_bib0043","first-page":"386","article-title":"The fragility index in randomized clinical trials supporting clinical practice guidelines for acute coronary syndrome: measuring robustness from a different perspective","volume":"12","author":"Gonzalez-Del-Hoyo","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323006137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323006137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:31:00Z","timestamp":1757583060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934323006137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0002934323006137"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.09.021","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}